A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis
Recruiting · Phase 2, Phase 3 · NCT06055959
Conditions: Generalized Myasthenia Gravis
At a glance
- Research payments reported, 2025
- $116,368
- U.S. investigators named
- 6
- Sites paid
- 4
- Planned or actual enrollment
- 8
About the trial
- Sponsor
- UCB Biopharma SRL
- Tested
- Zilucoplan (drug)
- Dates
- Started 2024-10-16; completion 2027-06-22
- Results posted
- Not yet
The purpose of this study is to assess the pharmacokinetics, pharmacodynamics, safety, tolerability, immunogenicity and activity of zilucoplan (ZLP) in pediatric study participants with generalized myasthenia gravis (gMG).
From ClinicalTrials.gov, last updated 2026-11-05. Full record, eligibility and contacts (opens in a new tab)
Industry funding
UCB SA reported $116,368 in research payments for this study in 2025 (7 payments).
Products named: Zilbrysq
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Nancy L. Kuntz, M.D. Child Neurology · Chicago, IL
- Abigail N. Schwaede, MD Physical Medicine & Rehabilitation (PM&R) · Chicago, IL
- Meriem K. Bensalem-owen, MD Neurology · Lexington, KY
- Yash D. Shah, M.D. Child Neurology · Baton Rouge, LA
- John F. Brandsema, MD Child Neurology · Philadelphia, PA
- Kaitlin Y. Batley, MD Child Neurology · Dallas, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- The University of Texas Southwestern Medical Center $55,215
- Children's Hospital of Philadelphia, PA $42,319
- Ann & Robert H Lurie Childrens Hospital of Chicago, IL $16,575
- Children's Medical Center of Dallas $2,259
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.